Drug Profile
Influenza A virus H1N1 vaccine - NuGenerex Immuno-Oncology
Alternative Names: AEA-35p; G4 EA H1N1 Swine Influenza Vaccine - NuGenerex Immuno-Oncology; li-Key-H1 peptide swine influenza vaccine - NuGenerex Immuno-Oncology; li-Key-H1 swine influenza vaccineLatest Information Update: 07 Dec 2020
Price :
$50
*
At a glance
- Originator Antigen Express
- Developer NuGenerex Immuno-Oncology
- Class Influenza A virus H1N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H1N1 subtype
Most Recent Events
- 20 Nov 2020 Generex entered a worldwide licensing agreement with consortium of partners in China to develop G4 EA H1N1 influenza vaccine
- 02 Jul 2020 NuGenerex Immuno-Oncology plans development of influenza A virus H1N1 vaccine for G4 EA H1N1 swine influenza virus strain
- 28 Apr 2018 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype in Unknown